BPC-157 (Body Protection Compound-157) for Researchers, Scientists, and Chemical Suppliers Disclaimer: BPC-157 is sold only for research and is not a medicinal product
BMI and Health Condition Requirements Eligibility for GLP-1 medications such as Ozempic often includes one of the following: A BMI of 30 or higher, which falls within the medical definition of obesity A BMI of 27 or higher with at least one weight-related health condition Weight-related conditions that may support eligibility include: High blood pressure (hypertension): Excess weight increases strain on your heart and blood vessels, raising long-term cardiovascular risk
The nitric oxide system also responds to BPC-157 administration
5,6 In a 12-week randomized trial, supplementation with 1,200 mg per day of berberine and 600 mg per day of cinnamon significantly reduced fasting blood glucose, HbA1c, and low-density lipoprotein (LDL) levels in patients with type 2 diabetes, without producing significant changes in body weight or BMI
It is not approved as a drug or dietary ingredient
Real-world experience from clinical programs and observational cohorts reinforce trial data and demonstrate more heterogeneity
